Fertiprot presentation pitch final for shenzhen translated 3.4.17
•Als PPTX, PDF herunterladen•
0 gefällt mir•66 views
This is the presentation we presented at the Shenzhen start-up competition on April 2017.
Empfohlen
Weitere ähnliche Inhalte
Was ist angesagt?
Was ist angesagt? (12)
Ähnlich wie Fertiprot presentation pitch final for shenzhen translated 3.4.17
Ähnlich wie Fertiprot presentation pitch final for shenzhen translated 3.4.17 (20)
Kürzlich hochgeladen
Kürzlich hochgeladen (20)
Fertiprot presentation pitch final for shenzhen translated 3.4.17
- 1. Increase Take- Home Baby Rate 增加生育机率 促生育力蛋白质
- 2. 生育
- 3. Vision: Creating Lives 愿景：创造生命 Crossing through the barrier and increase Take-Home Baby Rate A Drug Eluting Vaginal Ring For Fertility Enhancement and Increasing Chances for a Safer, a Quicker and a Healthier Pregnancy
- 4. A Vaginal Ring to Replace IVF 一种可替代IVF 的阴道环 IVF is a Painful, Invasive and Dangerous Procedure FertiProt can Reduce the Need for IVF for 20% - 30% of Couples, and increase Success Rates FertiProt will Increase Probability of Conception by Sexual Intercourse
- 5. The Problem 问题 WERE FOUND ELIGIBLE IN CHINA only 20%of donors One of every Seven (14.3%) couples encounters fertility problems, this number increases with age
- 8. FertiProt’s Solution (解决方案): A Drug Releasing Vaginal Ring for Slow Release of a Sperm Enhancing Factor 一种可以释放精子增强因子的阴道环
- 9. Innovative solution 是创新型药物解决方案 Known drugs that enhance sperm quality, including Motility, Endurance, Penetrability and Acrosome activation. Increase Implantation rates following fertilization, IUI or through IVF. Allow for further options like gender probability increase and selection. A Drug Eluting Vaginal Ring that will Increase conception rate with a normal Sexual Intercourse and without the need for invasive measures like IVF, for 20% - 30% of couples.
- 10. A-Z New Drug Application in up to 6Y 为期6年的A-Z 新型药品申请 Year 1 Year 2 Year 3 Year 4 Year 5 Year 6 Screening and POC Formulation (CMC) Preclinical and safety Phase 1 (PK) - FIH IND Preclinical and safety (NDA enabling) Phase 2 – 3 (efficacy studies) NDA $500 – 1M $500 – 1M $500K – 2M $2 – 3M $30 – 50M $1 – 2M • FDA Fast Track process (505(b)(2)) >> 7-10 years Exclusivity • Repurposing of a known/marketed drug-device combination • Pre clinical safety and PK (no efficacy needed in animals) • No dedicated Phase-2 needed • Short & clear cut Phase-3 (Yes/No pregnancy test)
- 11. Why Now? Why China? 为什么现在？为什么中国？ of Chinese young men had a poor sperm quality Following the new “2nd baby” policy initiated in China 1/7 2nd Baby 80%couples suffer from impaired fertility
- 12. Competitive Analysis 竞争力分析 Fertiprot's technology aims at reducing the need for Assisted Reproductive Treatment and more particularly IVF / ICSI Fertiprot’s Vaginal Ring is safe and could be self applied, at home with no medical intervention. Fertiprot's technology will increase potential for Gender selection Fertiprot's Vaginal Ring might become an OTC product
- 14. Business Opportunity 商业机遇 Fertility and IVF market is estimated at $50B/year by 2017 - FertiProt’s market share will be 15%
- 15. Team 团队 Lior Wayn – Co Founder & CEO A serial entrepreneur in the life sciences arena, where he led multiple public and private companies and have vast experience in taking concepts all the way to the market. Founder of 4 startups, holds 2 patents, with 18 years of management, entrepreneurship, innovation and BizDev experience. Dr. Ronen Shemesh – Founder & VP R&D Innovator and drug discovery expert. 22 years’ experience in the Biotech Industry both as research manager and business development. High expertise in project management, and research planning and execution (In all stages of drug development). Dr. Arik Kahane- Fertility consultant Deputy head of the ‘Assuta’ Hospital in ISRAEL, Manager of the 2nd largest fertility lab in ISRAEL and expert at fertility medicine and women’s health, head of the ‘Assuta’ Helsinki committee.
- 16. “There is nothing like it, and if there was, Fertility specialists would GLADLY suggest this to patients either before going into any conventional treatment, or alongside with advanced treatment, be it any state of any art...” (Dr. Arik Kahane) Thank Y u ! 谢谢您
Hinweis der Redaktion
- Proud to be here… I thank you for the opportunity to present Fertiprot.
- “Have anyone of you ever play with Dolls? Play ‘House’” Having kids is everyone’s dream. Fertiprot was founded a few years ago with the aspiration of bringing happiness and fulfill the dream of many people: Start a family!!! and “Create Lives”. We believe in “Crossing through the barrier for more efficient reproduction and increase Take-Home Baby Rate for infertile couples”, for which this dream could not be fulfilled.
- For some of us, the dream has become a nightmare. One of seven couples trying to conceive will encounter problems, and the current solution, IVF, is a Painful, Invasive and Dangerous Procedure that involves painful daily injections, hormonal therapy, invasive procedures, stress, an emotional rollercoaster and side effects including obesity and even cancer. FertiProt can Reduce the Need for IVF for 20% - 30% of couples, and increase success rates. Our solution resides in a drug formulation that will improve sperm activity, including Motility, Endurance and Penetrability. This will be achieved by: A Vaginal Ring that will Increase Probability of Sexual Conception, Implantation, and Allow Gender Probability Selection.
- The problem of infertility is now an escalating problem. With almost 80% of sperm donors in China found non-suitable for donation, and one in every seven couples suffer from impaired fertility, and the number is growing.
- Our solution is a simple device, a vaginal ring that slowly but continuously release a drug that will increase sperm activities within the female system. This device can be used at home, within fertility time window, with no pain or hassle.
- FertiProt’s Innovative solution: A Vaginal Ring that will Increase sperm activity, and thus fertilization and Take-Home Baby Rate with a normal Sexual Intercourse and without the need for invasive measures like IVF, for 20% - 30% of couples that are borderline or subfertile. Our drug formulation will also Increase Implantation rates following fertilization, IUI or through IVF. The increase in sperm activity will cause Enhancement of Intra-Uterine Insemination (IUI) efficiency and Success rates. Selecting which sperm factor to enhance (motility for males and endurance for females) will Allow for further options like gender probability increase and selection.
- A known drug – repurposing: Development is short and cheap with estimated time to market is under 6 years and cost is estimated at $50M- $80M. FDA Fast Track process (505(b)(2) ) >> Exclusivity Repurposing of a known/marketed drug device combination Pre clinical safety and PK (no efficacy) No Phase-2 needed as dose and safety are established Short & clear cut Phase-3
- These days, world infertility is as high as one in every seven couples, and especially in China, with the new 2nd baby law implemented and the fact that male fertility is so low, with only 20% of young men eligible for donating their sperm.
- The only real competition is In Vitro Fertilization (IVF)… Fertiprot's technology reducing the need for Assisted Reproductive Treatment and more particularly IVF / ICSI Fertiprot's technology will increase potential for Gender selection Fertiprot's Vaginal Ring might become an OTC product
- A few words about gender selection: In the long run, Fertiprots technology will replace some non-validated traditional methods such as charts for gender selection.
- Business opportunity: Fertility and IVF market is estimated at $50B/year by 2017 - FertiProt’s market share will be around 15%
- Our leading team includes a Fertility Expert, a Veteran Business and Marketing Expert and an Experienced Scientist and Innovator.
- With that, I would like to thank you and leave you with a quote made by our fertility expert, Dr. Arik Kahane, while taking your questions.